BR112023024146A2 - Métodos de tratamento de distúrbios relacionados às mitocôndrias - Google Patents
Métodos de tratamento de distúrbios relacionados às mitocôndriasInfo
- Publication number
- BR112023024146A2 BR112023024146A2 BR112023024146A BR112023024146A BR112023024146A2 BR 112023024146 A2 BR112023024146 A2 BR 112023024146A2 BR 112023024146 A BR112023024146 A BR 112023024146A BR 112023024146 A BR112023024146 A BR 112023024146A BR 112023024146 A2 BR112023024146 A2 BR 112023024146A2
- Authority
- BR
- Brazil
- Prior art keywords
- mitochondria
- treatment
- methods
- methyl
- disorders related
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191321P | 2021-05-20 | 2021-05-20 | |
| US202163222841P | 2021-07-16 | 2021-07-16 | |
| US202263307515P | 2022-02-07 | 2022-02-07 | |
| PCT/US2022/029992 WO2022246039A1 (en) | 2021-05-20 | 2022-05-19 | Methods of treating mitochondria-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024146A2 true BR112023024146A2 (pt) | 2024-01-30 |
Family
ID=82020295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024146A BR112023024146A2 (pt) | 2021-05-20 | 2022-05-19 | Métodos de tratamento de distúrbios relacionados às mitocôndrias |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250177353A1 (https=) |
| EP (1) | EP4340829A1 (https=) |
| JP (1) | JP2024521709A (https=) |
| KR (1) | KR20240021827A (https=) |
| AU (1) | AU2022275935A1 (https=) |
| BR (1) | BR112023024146A2 (https=) |
| CA (1) | CA3219548A1 (https=) |
| CL (1) | CL2023003441A1 (https=) |
| GE (1) | GEAP202416398A (https=) |
| IL (1) | IL308669A (https=) |
| JO (1) | JOP20230298A1 (https=) |
| MX (1) | MX2023013688A (https=) |
| TW (1) | TW202313010A (https=) |
| WO (1) | WO2022246039A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150759A1 (en) * | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss in a subject with elevated hba1c |
| TW202515545A (zh) * | 2023-08-10 | 2025-04-16 | 大陸商深圳君聖泰生物技術有限公司 | ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1098641B1 (en) | 1998-07-27 | 2016-04-27 | St. Jude Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| PT3565806T (pt) | 2017-01-06 | 2022-05-19 | Rivus Pharmaceuticals Inc | Novos derivados de fenilo |
-
2022
- 2022-05-19 WO PCT/US2022/029992 patent/WO2022246039A1/en not_active Ceased
- 2022-05-19 KR KR1020237043901A patent/KR20240021827A/ko active Pending
- 2022-05-19 BR BR112023024146A patent/BR112023024146A2/pt unknown
- 2022-05-19 AU AU2022275935A patent/AU2022275935A1/en active Pending
- 2022-05-19 IL IL308669A patent/IL308669A/en unknown
- 2022-05-19 JP JP2023571818A patent/JP2024521709A/ja active Pending
- 2022-05-19 GE GEAP202416398A patent/GEAP202416398A/en unknown
- 2022-05-19 MX MX2023013688A patent/MX2023013688A/es unknown
- 2022-05-19 US US18/562,560 patent/US20250177353A1/en active Pending
- 2022-05-19 EP EP22729956.7A patent/EP4340829A1/en active Pending
- 2022-05-19 CA CA3219548A patent/CA3219548A1/en active Pending
- 2022-05-20 TW TW111118998A patent/TW202313010A/zh unknown
-
2023
- 2023-11-19 JO JOJO/P/2023/0298A patent/JOP20230298A1/ar unknown
- 2023-11-20 CL CL2023003441A patent/CL2023003441A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4340829A1 (en) | 2024-03-27 |
| KR20240021827A (ko) | 2024-02-19 |
| JP2024521709A (ja) | 2024-06-04 |
| CL2023003441A1 (es) | 2024-05-10 |
| JOP20230298A1 (ar) | 2023-11-19 |
| US20250177353A1 (en) | 2025-06-05 |
| TW202313010A (zh) | 2023-04-01 |
| WO2022246039A1 (en) | 2022-11-24 |
| AU2022275935A1 (en) | 2023-12-07 |
| CA3219548A1 (en) | 2022-11-24 |
| MX2023013688A (es) | 2024-02-27 |
| GEAP202416398A (en) | 2024-01-25 |
| IL308669A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serebrovskaya et al. | Intermittent hypoxia: cause of or therapy for systemic hypertension? | |
| BR112023024146A2 (pt) | Métodos de tratamento de distúrbios relacionados às mitocôndrias | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| NO20053678L (no) | Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser | |
| BR0309670A (pt) | Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| HUP0301146A2 (hu) | 2-Klór-5-nitrofenil karboxamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| BR112023017648A2 (pt) | Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk | |
| Wang et al. | Spinal microglial activation promotes perioperative social defeat stress-induced prolonged postoperative pain in a sex-dependent manner | |
| EP1948161A4 (en) | METHOD FOR PREVENTING AND TREATING PPAR-MEDIATED CONDITIONS WITH MACELIGNAN | |
| BR112023017999A2 (pt) | Obicetrapibe para tratamento de demências | |
| CY1111783T1 (el) | Θεραπεια συνδυασμου διαταραχων κατωτερης ουροποιητικης οδου με 2 προσδεματα και μη στεροειδες αντιφλεγμονωδες φαρμακο | |
| BR112022008095A2 (pt) | Métodos e composições para o tratamento da síndrome de rett | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| Wang et al. | Changes in plasma angiotensin II and circadian rhythm of blood pressure in hypertensive patients with sleep apnea syndrome before and after treatment | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| Cheng et al. | Berberine reverses impaired adipose angiogenesis to promote beige adipogenesis by HIF-1α/PRDM16 signaling | |
| BR0009143A (pt) | Mediação inflamatória obtida de atractylodeslancea | |
| EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
| RU2594252C1 (ru) | Способ реабилитации больных алкогольной полинейропатией | |
| Malchenko | In-depth investigation of analgesic activity of N-(4-methoxybenzyl)-4-methyl-2.2-dioxo-1H-2 λ6. 1-benzothiazine-3-carboxamide derivate on different models of pain perception | |
| BR112022023428A2 (pt) | Tratamento do transtorno de adaptação | |
| EA200702534A1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2) |